Century Therapeutics (IPSC) Liabilities and Shareholders Equity (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $326.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $326.6 million, up 3.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 26.75% YoY), and the FY2025 annual result was $223.7 million, down 36.67% from the prior year.
• Liabilities and Shareholders Equity climbed to $326.6 million in Q1 2026 per IPSC's latest filing, from $223.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $550.3 million in Q1 2022 and troughed at $223.7 million in Q4 2025.
• A 5-year average of $389.1 million and a median of $388.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity increased 11.24% in 2022, then sank 37.03% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $486.5 million in 2022, then declined by 25.87% to $360.7 million in 2023, then fell by 2.07% to $353.2 million in 2024, then sank by 36.67% to $223.7 million in 2025, then soared by 45.98% to $326.6 million in 2026.
• Business Quant data shows IPSC's Liabilities and Shareholders Equity at $326.6 million in Q1 2026, $223.7 million in Q4 2025, and $244.7 million in Q3 2025.